Welcome to the Working Group on New TB Drugs Blog
Interview with TB Alert’s Mike Mandelbaum
Mike Mandelbaum is Chief Executive of TB Alert, which is the UK’s National and International Tuberculosis charity – the only British charity working solely on fighting TB in the UK and overseas.
TB R&D Weekly Update: P27-P55 Operon of Mtb and Drug Resistance
his week, we present an article from researchers from the Instituto de Biotecnologia and TB Control Program in Buenos Aires, Argentina. The article focuses on the P27-P55 operon which has been shown in mice to be essential for M. tuberculosis (M. tb) to survive in the host. Additional links to TB R&D news are included.
Report: An Evaluation of DR-TB Treatment Scale-up
MSF, PIH, and TAG release a report on MDR-TB scale up that shows poor progress that is leading to spread of MDR-TB and the continued loss of lives.
TB R&D Weekly Update: Early bactericidal activity of OPC-67683
This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity. Links to additional TB R&D news is included.
Posted in TB News, TB Pediatrics, TB Prevention and Control Strategies, TB Treatment, Uncategorized
TB R&D Weekly Update: Latent TB Treatment in HIV and Children
In the July 7 issue of the New England Journal, two articles and an editorial on latent TB and TB prevention are published. One study discusses positive results on a treatment for latent TB in HIV-infected persons. The other study discusses negative findings that isoniazid is not effective in latent treatment of tuberculosis in children regardless of HIV status. A link to MedPage Today is included that provides a good overview of these studies and the editorial. Additional TB R&D News Links also are included.
Posted in TB Patient Perspective, TB Prevention and Control Strategies, Video, Voices from the Fight to Stop Tuberculosis
Video: Jenniffer Dietrich, Challenge Facility for Civil Society
Jenniffer Dietrich is Technical Officer at the Challenge Facility for Civil Society of the Stop TB Partnership.
TB R&D Weekly Update: Tuberculosis and Cancer
This week we review a commentary on the correlations between tuberculosis and cancer, specifically lung cancer. The article appeared in the June issue of Lancet Oncology. Additional links to TB R&D News are included.
Video: Global Fund in the Dominican Republic
This video documents what the Global Fund has done and can do more of to save lives and prevent infections by engaging affected communities.
TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB
During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Links to additional TB R&D News are included.
Posted in TB Prevention and Control Strategies, Video, Voices from the Fight to Stop Tuberculosis
Video: Global Fund Impact in Indonesia
This video presents interviews with a diverse range of stakeholders on the positive impact that Global Fund financing has had for Indonesia’s national programme. This post also includes another perspective from Kenya.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
